NCT02749136 - Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

September 30, 2019

Study Completion Date

November 30, 2019

Conditions

Pancreatic Adenocarcinoma

Interventions

DRUG

Preoperative modified FOLFIRINOX and postoperative gemcitabine

"* Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles~ * Oxaliplatin IV 85 mg/m2 Day (D) 1~ * Irinotecan IV 180 mg/m2 D1~ * 5-FU continuous IV infusion 2,400 mg/m2 over 46 hours D1-2~ * Leucovorin IV 400 mg/m2 D1~* Postoperative gemcitabine, every 4 weeks, 3-6 cycles - Gemcitabine 1,000 mg/ m2 D1, 8, and 15"

Trial Locations (1)

05505

Asan Medical Center, University of Ulsan College of Medicine, Seoul